Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cephalon
• Treatments: Fentanyl

Criteria

Inclusion Criteria:

• Documented diagnosis of a malignant solid tumor or hematological malignancy causing cancer related pain

• Currently taking around the clock opioid therapy for pain

• Experience on average, 1-4 breakthrough pain episodes per day

Exclusion Criteria:

• Opioid or fentanyl intolerance

• Sleep apnea or active brain metastases with increased intracranial pressure

• COPD (chronic obstructive pulmonary disease); cardiopulmonary disease; heart disease